TSHA
Taysha Gene Therapies, Inc.Company Information
- Company Name
- Taysha Gene Therapies, Inc.
- CIK
- CIK0001806310
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- TSHA: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- TSHA
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-05-30
- Last sale
- 2026-07-10
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 1,265,326
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 301,110,801
- Shares outstanding
- 369,044,040
- Ownership
- 81.59%
Earnings Market Reaction
- Filing date
- 2026-08-11
- Price on filing date
- —
- 1-month reaction
- -16.17%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 455 | 277 | 320 | 297 | 313 | 117 | 139 | 158 | 173 | 124 | 144 | 164 | ||||||
| Restricted Cash Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Prepaid Expense And Other Assets Current | 6 | 5 | 4 | 2 | 3 | 4 | 3 | 3 | 3 | 4 | 3 | 6 | ||||||
| Assets Held For Sale Not Part Of Disposal Group Current | - | - | - | - | - | - | - | - | 2 | 2 | 2 | 2 | ||||||
| Assets Current | 461 | 282 | 325 | 300 | 316 | 121 | 142 | 162 | 178 | 131 | 150 | 172 | ||||||
| Restricted Cash | - | - | - | - | - | - | - | - | - | - | - | 3 | ||||||
| Restricted Cash Noncurrent | 0 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | - | ||||||
| Property Plant And Equipment Net | 2 | 6 | 7 | 7 | 7 | 7 | 7 | 8 | 11 | 11 | 11 | 11 | ||||||
| Operating Lease Right Of Use Asset | 6 | 9 | 9 | 7 | 8 | 8 | 8 | 9 | 9 | 9 | 10 | 10 | ||||||
| Other Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets | 470 | 300 | 343 | 317 | 333 | 138 | 160 | 180 | 200 | 153 | 173 | 196 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 9 | 5 | 6 | 5 | 8 | 4 | 4 | 5 | 9 | 10 | 6 | 8 | ||||||
| Accrued Liabilities And Other Liabilities | 17 | 16 | 20 | 18 | 12 | 11 | 13 | 13 | 12 | 14 | 12 | 14 | ||||||
| Deferred Revenue Current | - | - | - | 5 | 5 | 7 | 10 | 12 | 14 | 15 | 18 | 19 | ||||||
| Derivative Liabilities Current | - | - | - | - | - | - | - | - | - | - | - | 141 | ||||||
| Liabilities Current | 26 | 20 | 27 | 29 | 25 | 23 | 26 | 29 | 34 | 39 | 37 | 180 | ||||||
| Deferred Revenue Noncurrent | - | - | - | - | - | - | - | - | - | - | - | 3 | ||||||
| Long Term Debt Noncurrent | 49 | 49 | 50 | 51 | 41 | 42 | 44 | 43 | 38 | 41 | 41 | 39 | ||||||
| Operating Lease Liability Noncurrent | 6 | 18 | 18 | 17 | 17 | 17 | 17 | 18 | 18 | 18 | 19 | 19 | ||||||
| Other Liabilities Noncurrent | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 4 | ||||||
| Liabilities | 83 | 88 | 96 | 98 | 85 | 83 | 89 | 91 | 92 | 99 | 98 | 245 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 1,187 | 965 | 958 | 904 | 900 | 681 | 678 | 675 | 664 | 591 | 588 | 512 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | 1 | 1 | -0 | -1 | -1 | -2 | -4 | -2 | 2 | -0 | - | - | ||||||
| Retained Earnings Accumulated Deficit | -800 | -754 | -711 | -683 | -651 | -624 | -602 | -584 | -558 | -537 | -513 | -561 | ||||||
| Stockholders Equity | 387 | 212 | 247 | 219 | 249 | 55 | 72 | 89 | 109 | 54 | 75 | -49 | ||||||
| Liabilities And Stockholders Equity | 470 | 300 | 343 | 317 | 333 | 138 | 160 | 180 | 200 | 153 | 173 | 196 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 700 | 700 | 700 | 700 | 700 | 400 | 400 | 400 | 400 | 400 | 400 | 200 | ||||||
| Common Stock Shares Issued | 325 | 287 | 285 | 274 | 273 | 205 | 205 | 205 | 201 | 187 | 187 | 187 | ||||||
| Shares Outstanding | 325 | 287 | 285 | 274 | 273 | 205 | 205 | 205 | 201 | 187 | 187 | 187 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialTaysha Gene Therapies, Inc. (TSHA) — SEC Financial Statements & Analysis
Taysha Gene Therapies, Inc. (TSHA) is a biological products, (no diagnostic substances) company, incorporated in DE. Taysha Gene Therapies, Inc. trades on Nasdaq as: TSHA. Taysha Gene Therapies, Inc. (TSHA)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-11. Based on that filing, Taysha Gene Therapies, Inc. carries a market cap of $2.51B, a P/E ratio of -16.80x, a P/B ratio of 6.49x, a P/S ratio of 458.19x, an enterprise value of $2.11B, and an EV/EBITDA multiple of -13.87x. On profitability, it posts a gross margin of 117.40%, an operating margin of -2792.32%, a net margin of -2728.04%, a Return on Equity (ROE) of -47.05%, and a Return on Assets (ROA) of -37.23%. Per share, it reports EPS of $-0.41, diluted EPS of $-0.41, free cash flow per share of $-0.36, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -32.27% year-over-year, net income growth of 61.38% year-over-year, and EPS growth of 30.31% year-over-year. On the balance sheet, it maintains a current ratio of 17.76x, a quick ratio of 17.53x, working capital of $435.46M, a debt-to-equity ratio of 0.21x, a debt ratio of 0.18, an interest coverage ratio of -3646.64x, free cash flow of $-132.57M (TTM), and net debt of $-406.15M. Figures sourced from SEC EDGAR.
- Market Cap
- $2.51B
- P/E TTM
- -16.80x
- EPS TTM
- $-0.41
- P/B TTM
- 6.49x
- ROE TTM
- -47.05%
- ROA TTM
- -37.23%
- Debt To Equity
- 0.21x
- Free Cash Flow TTM
- $-132.57M
- Net Revenue TTM Growth 1Y
- -32.27%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Taysha Gene Therapies, Inc. in?
Taysha Gene Therapies, Inc. (TSHA) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does TSHA trade on?
Taysha Gene Therapies, Inc. (TSHA) trades on the Nasdaq.
Where is Taysha Gene Therapies, Inc. incorporated?
Taysha Gene Therapies, Inc. is incorporated in DE.
When was Taysha Gene Therapies, Inc. (TSHA)'s most recent SEC filing?
Taysha Gene Therapies, Inc. (TSHA)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-11.
What is TSHA's market cap?
Taysha Gene Therapies, Inc. (TSHA) has a market capitalization of $2.51B as of 2026-06-30.
What is TSHA's EPS (earnings per share)?
Taysha Gene Therapies, Inc. (TSHA)'s trailing twelve month EPS is $-0.41 as of 2026-06-30.
What is TSHA's ROE (return on equity)?
Taysha Gene Therapies, Inc. (TSHA)'s trailing twelve month Return on Equity (ROE) is -47.05% as of 2026-06-30.
What is TSHA's ROA (return on assets)?
Taysha Gene Therapies, Inc. (TSHA)'s trailing twelve month Return on Assets (ROA) is -37.23% as of 2026-06-30.
What is TSHA's EV/EBITDA?
Taysha Gene Therapies, Inc. (TSHA)'s trailing twelve month EV/EBITDA is -13.87x as of 2026-06-30.